Romiplostim
Orphan Drug Cold Chain RequiredFDA Approved
Description
Romiplostim is a thrombopoietin (TPO) receptor agonist. It is used to treat thrombocytopenia in adults with immune thrombocytopenic purpura (ITP).
Indications & Therapeutic Use
Autoimmune thrombocytopenia
Linked Diseases:
Global Availability (5 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Romiplostim
| Generic Name | Romiplostim |
| Brands | 1 brand available |
| Active Ingredient | Romiplostim |
| Drug Class | Autoimmune thrombocytopenia |
| Manufacturer | Amgen |
| Dosage Forms | Subcutaneous injection, 250 mcg/vial, 500 mcg/vial |
| Medical Code | B02BX04 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00109453 |
| Countries | 5 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations6 Validated Nodes